The influence of antiestrogens on pS2 and cathepsin D mRNA induction in MCF-7 breast cancer cells

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 837-842

  Rajah, Talitha T ^a   Terence Dunn, S ^b   Pento, J Thomas ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Antiestrogens; Breast cancer cells; Cathepsin D gene; Gene regulation; Ps2 gene

Indexed keywords

1,1 DICHLORO 2,3 DIPHENYLCYCLOPROPANE; ANTIESTROGEN; CATHEPSIN D; ESTROGEN RECEPTOR; FULVESTRANT; MESSENGER RNA; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; DRUG MECHANISM; GENE CONTROL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BREAST NEOPLASMS; CATHEPSIN D; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION; HUMANS; NEOPLASM PROTEINS; PROTEINS; RNA, MESSENGER; TAMOXIFEN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 0030010755     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Jordan VC, Muphy CS: Endocrine pharmacology of antiestrogens as antitumor agents. Endocrine Rev 11: 578, 1990.
2. Oshorne CK, Coronado EB, Robinson JR: Human breast cancer in athymic mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23: 1189-1196, 1987.
3. Fornander T, Cedermark B, Mattsson A, Skoog L, Theve T, Askergren J, Rutqvist LE, Glas U, Silfversward C, Somell A, Wilking N, Hjalmar M: Adjuvant tamoxifen in early breast cancer: occupance of new primary cancers. Lancet 1: 117-119, 1989.
4. Boccaardo F, Bruzzi P, Rubagotti A, Nicolo G, Rosso R: Estrogenlike action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 38: 281-285, 1981.
5. Fentiman IS, Powles TJ: Tamoxifen and benign breast problems. Lancet 2(8567): 1070-1071, 1987.
6. Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogen. Cancer Treat Rep 69: 237-238, 1985.
7. Clarke R, Thompson EW, Leonessa F, Lippman J, McGarvey M, Frandsen TL, Brunner N: Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res Treat 24: 227-239, 1993.
8. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumor in athymic mouse after long-term tamoxifen administration. Cancer Res 48: 5183-5188, 1988.
9. Black LJ, Jones CD, Falcone JF: Antagonism of estrogen action with new benzothiophene-derived antiestrogen. Life Sci 32: 1031-1036, 1983.
10. Day BW, Magarian RA, Jain PT, Pento JT, Mousissian GK, Meyer K: Synthesis and biological evaluation of a series of 1,1- Dichloro-2,2.3-triaryl cyclopropanes as pure antiestrogens. J Med Chem 34: 842-851, 1991.
11. Wakeling AE, Bowler J: Novel antiestrogens without partial agonist activity. J Steroid Biochem 31: 645-653, 1988.
12. Thompson EW, Katz D, Shima TB, Wakeling AE, Lippman M, Dickson RB: ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res 49: 6929-6934, 1989.
13. Wakeling AE, Newboult E, Peters SW: Effects of antiestrogens on the proliferation of MCF-7 human breast cancer cells. J Mol Endo 2: 225-234, 1989.
14. Griffin MT, Magarian RA, Jain P, Pento JT, Mousissian GK, Graves DC: Synthesis and biological evaluation of a series of gemdichlorocyclopropanes as antitumor agents. AntiCancer Drug Design 7: 49-66, 1992.
15. Jain PT, Pento JT, Magarian RA: The influence of a novel cyclopropyl antiestrogen (compound 7a) on human breast cancer cells in culture. Breast Cancer Res Treatment 25: 225-233, 1993.
16. Stobaugh JF, Magarian RA, Pento JT: Synthesis and biological evaluation of gemdichlorocyclopropyl analogs of stilbene congeners as potential antiestrogens. J Pharm Sci 71: 1126-1129, 1982.
17. Jain PT, Pento JT, Magarian RA, Graves DC: Cytotoxicity of Analog II in human breast cancer cells in culture. The Toxicologist 11(1): 157, 1991.
18. Roberts M, Wallace J, Jeltsch JM, Berry M: The 5' flanking region of the human pS2 gene mediates its transcriptional activation by estrogen in MCF-7 cells. Biochem Biophys Res Comm 151: 306-313, 1988.
19. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P: Functional domains of the human estrogen receptor. Cell 51: 941-951, 1987.
20. Klein-Hitpass L, Schorpp M, Wagner U, Ruffel GU: An estrogen responsive element derived from the 5' flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 46: 1053-1061, 1986.
21. Cavailles V, Angerean P, Rochefort H: Cathepsin D is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells. Proc Natl Acad Sci U.S.A. 90: 203-207, 1993.
22. Chalbos D, Philips A, Galteir F, Rochefort H: Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3′ 5′ monophosphate in MCF-7 cells. Endocrinology 133(2): 571-576, 1993.
23. Jain PT, Pento JT: A vehicle for the evaluation of hydrophobic compounds in cell culture. Res Comm Chem Path Pharm 74: 105-116, 1991.
24. Lin X, Dashti A, Schinazi RF, Tang J: Intracellular diversion of glycoprotein GP160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy. FASEB Journal 7(11): 1070-80, 1993.
25. Jain PT, Pento JT, Magarian RA, Graves DC: Antiproliferative activity of a series of novel antiestrogens on MCF-7 human breast cancer cells in culture. Anticancer Drugs 2: 487-493, 1991.
26. Pilat MJ, Hafner MS, Kral LG, Brooks SC: Differential induction of pS2 and cathepsin D mRNAs by structurally altered estrogens. Biochem 32: 7009-7015, 1993.
27. Dauvois S, White R, Parker MG: The antiestrogen ICI 182, 780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106: 1377-88, 1993.
28. Dauvois S, Danielian PS, White R, Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen content by increasing its turnover. Proc Nad Acad Sci U.S.A. 89: 4037-41, 1992.
29. Webster NJG, Green S, Jin JR, Chambon P: The hormone binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54: 199-207, 1988.
30. Johnson MD, Westley BR, May FEB: Estrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Br J Cancer 59: 727-738, 1989.
31. Wesdey B, May FEB, Brown AMC, Krust A, Chambon P, Lippmann ME, Rochefort H: Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160 kilodalton proteins in MCF-7 cells and two tamoxifen resistant sublines. J Biol Chem 259: (16): 10030-10035, 1984.
32. Nunez AM, Berry M, Imler JL, Chambon P: The 5 flanking region of pS2 gene contains a complex enhancer region responsive to estrogens, epidermal growth factor, a tumor promoter (TPA), the c-Ha-ras oncoprotein and the cjun protein. The EMBO Journal 8(3): 823-829, 1989.
33. Rochefort H, Bardon S, Chalbos D, Vignon F: Steroidal and nonsteroidal antiestrogen breast cancer cells in culture. J Steroidal Biochem 20: 105-110, 1984.
34. Rochefort H: Cathepsin D in breast cancer: a tissue marker associated with metastasis. Euro J Cancer 28A(11): 1780-3, 1992.